SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced today the addition of differentiated Cryo-M Human Monocytes to their AccuCell? peripheral blood mononuclear cell (PBMC) portfolio. SeraCare's Cryo-M cells provide researchers with a high quality, specialized and unstimulated cell line to study gene expression, immune and inflammatory responses. This product is manufactured from standardized, quality-controlled sole source lots, allowing for consistent and reproducible results. This is the third in a series of new cellular products and the twenty-first new product introduced to SeraCare's overall portfolio over the last 18 months.

"SeraCare is focused on building the most comprehensive library of exceptional quality cellular products available on the market," said Susan Vogt, President and Chief Executive Officer of SeraCare. "Our growing portfolio of large-lot, same-donor, cryopreserved primary cells are superior to other offerings because they demonstrate reduced variability from assay to assay, meeting an important research need. The cellular product portfolio is a core component of SeraCare's growth strategy and is expected to increase margin performance and topline revenue growth."

About SeraCare Life Sciences, Inc.

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, prolonged impairment of sales from changes in our sales organization, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

SeraCare Life Sciences, Inc.
Gregory A. Gould, 508-244-6400
Chief Financial Officer
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060